All Stories

Optibiotix – the good news keeps on coming : DO NOT SELL

Tom Winnifrith
Sunday 2 December 2018

On Tuesday we learned how Optibiotix (OPTI) had secured medical device approval for Slimbiome and a CE Mark and that it had been working on this for two and a half years. We suggested that it would thus hit the ground running and so it was perfectly plausible that it could be delivering annualised profits of £7 million from this one product within two years. On Thursday we saw evidence of how well prepared it is for a rapid rollout.

on ShareProphets | Comments
About Tom Winnifrith
Bio
Tom Winnifrith is the editor of TomWinnifrith.com. When he is not harvesting olives in Greece, he is (planning to) raise goats in Wales.
Twitter
@TomWinnifrith
Email
[email protected]
Recently Featured on ShareProphets
Sign up for my weekly newsletter








Required Reading

Recent Comments


I also read